logo
Share SHARE
FONT-SIZE Plus   Neg

CER Research Says Abbott's Response To Similac Test Results Irresponsible

Hong Kong-based CER Research Friday said Abbott Laboratories Inc.'s (ABT) response to the report released March 22 relating to the safety of the infant formula product Similac Stage 1 was "irresponsible." The report contained results which showed that the Abbott product, purchased in Hong Kong in December, failed two tests by a significant margin.

In its response, which, according to CER Research, was issued in Chinese, Abbott criticized the report for a lack of "scientific-ness, objectivity and fairness." CER Research's rebuttal claims that the results were obtained from "named and recognized laboratories and experts", adding that it has "no independent view" on the product. Further, CER Research said its attempts to contact Abbott were rebuffed.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Everyone knows that the Federal Reserve will raise interest rates next Wednesday at the conclusion of its two-day policy meeting. After all, Fed speakers have been jawboning a rate hike over the past few weeks. With the markets reacting with eerie calm to Donald Trump's win, policy makers have no... GOP strategist Karl Rove has criticized U.S. President-elect Donald Trump's comments on aircraft maker Boeing Co.'s contract for a new Air Force One plane, saying they were inaccurate and de-stabled the stock of a major company. Air Force One is the official air plane for the U.S. President. Elon Musk's space transport company SpaceX has lost a satellite launch order from one of its customers due to the delay in its rocket launch schedule after one of its rockets exploded in September.
comments powered by Disqus
Follow RTT